admin, Author at Xeltis

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council

Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP)…

admin In Latest News

Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology

Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement EINDHOVEN, The Netherlands, 11…

admin In Clinical Trials, Latest News

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2…

admin In Clinical Trials, Latest News

Xeltis announces FDA Breakthrough Device Designation for aXess™ and first patient treated in US pivotal trial

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages…

admin In Latest News

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership…

admin In Latest News

Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs

Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows…

admin In Clinical Trials, Latest News

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess™, its restorative vascular access conduit

aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent,…

admin In Events, Latest News

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

admin

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council

Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Xeltis announces FDA Breakthrough Device Designation for aXess™ and first patient treated in US pivotal trial

Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development

Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXess™, its restorative vascular access conduit

Xeltis Announces Latest Results from aXess™ Trials to be Presented at 46th Annual Charing Cross Symposium

ETR Insights from Xeltis restorative pulmonary valve in Acta Biomaterialia

Superior biocompatibility of Xeltis materials vs conventional heart valve devices published in JBMR